72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label ExtensionADVANCES IN THERAPYIF42018-09-1119OAAI
Efficacy and safety of delayed-release dimethyl fumarate in treatment-naive Japanese patients with relapsing-remitting multiple sclerosis: A post-hoc subgroup analysis of the apex studyJOURNAL OF THE NEUROLOGICAL SCIENCESIF3.22017-10-010PREAI
Safety of delayed-release dimetyl fumarate in Japanese patients with relapsing multiple sclerosis: Subgroup analysis of the apex Part 1 studyJOURNAL OF THE NEUROLOGICAL SCIENCESIF3.22017-10-010PREAI
Efficacy of delayed-release dimethyl fumarate in Japanese patients with relapsing multiple sclerosis in the placebo-controlled phase 3 apex studyJOURNAL OF THE NEUROLOGICAL SCIENCESIF3.22017-10-010PREAI
Safety and effectiveness of natalizumab: The 2-year interim results of the post-marketing surveillance in JapanJOURNAL OF THE NEUROLOGICAL SCIENCESIF3.22017-10-010PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向